In their own responses to the senators’ inquiries last fall, both Pfizer and Lilly emphasized the independence of their ...

Just two days after starting at the FDA, the agency’s Chief Counsel Hilary Perkins is signing off, effective immediately. | ...

In a year in which he faced down a challenge from an activist investor, Pfizer CEO Albert Bourla, Ph.D., received a 14% total ...

The U.K. government is proposing to raise the rebate rate under a national drug cost program, drawing complaints from the ...

Following a fire at a Bayer executive’s New Jersey home earlier this month, at least eight agencies—including the Federal ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Despite a rocky start for many drugmakers at the start of last year, 2024’s fourth quarter saw just two of the top 25 global ...

Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

AstraZeneca is hopping aboard the pickleball craze as its serves up a new marketing push for its asthma med Fasenra. | ...

Based on internal projections for demand, the two companies have approved about $150 million in additional investments to ...

Mallinckrodt and Endo are merging in a cash and stock deal worth some $6.7 billion, the companies said Thursday. Under the ...

Novartis has teamed up with the NFL in a multi-year partnership, marking the first such collaboration between the football ...